Formosa Pharmaceuticals, Inc. (TPE:6838)
Taiwan · Delayed Price · Currency is TWD 25.80
+0.15 (0.58%)
Sep 30, 2026, 1:30 PM CST
Formosa Pharmaceuticals Revenue
Formosa Pharmaceuticals had revenue of 3.03M TWD in the quarter ending June 30, 2026, a decrease of -36.48%. This brings the company's revenue in the last twelve months to 52.59M, up 237.39% year-over-year. In the year 2025, Formosa Pharmaceuticals had annual revenue of 9.50M, down -93.38%.
Revenue (ttm)
52.59M
Revenue Growth
+237.39%
P/S Ratio
73.64
Revenue / Employee
n/a
Employees
10
Market Cap
3.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.50M | -133.86M | -93.38% |
| Dec 31, 2024 | 143.36M | 112.18M | 359.89% |
| Dec 31, 2023 | 31.17M | 29.86M | 2,270.49% |
| Dec 31, 2022 | 1.32M | -27.21M | -95.39% |
| Dec 31, 2021 | 28.53M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| SYN-TECH Chem. & Pharm. | 1.27B |
| Mycenax Biotech | 815.87M |
| Sagittarius Life Science | 467.69M |
| BioGend Therapeutics | 236.58M |
| Pharmosa Biopharm | 53.38M |
| OBI Pharma | 52.20M |
| UnicoCell Biomed | 22.46M |
| BRIM Biotechnology | 10.60M |